Skip to main content

Intra-abdominal Infection

6
Pipeline Programs
3
Companies
7
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

On Market (1)

Approved therapies currently available

Pfizer
TYGACILApproved
tigecycline
Pfizer
Tetracycline-class Antibacterial [EPC]intravenous2005
85K Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
TigecyclinePhase 4Small Molecule5 trials
Study Evaluating the Etiology of Intra-Abdominal InfectionsN/A1 trial
Active Trials
NCT00244088Completed340Est. Dec 2004
NCT01721408Completed470Est. Oct 2015
NCT00488761Completed50Est. Aug 2007
+3 more trials
MSD
MSDIreland - Ballydine
2 programs
2
Comparator: ceftriaxone sodium / Duration of Treatment: 8 WeeksPhase 3
MK-7625A 1.5 gPhase 3
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
2
Comparator: ceftriaxone sodium / Duration of Treatment: 8 WeeksPhase 3
MK-7625A 1.5 gPhase 3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerTigecycline
PfizerTigecycline
PfizerTigecycline
PfizerTigecycline
PfizerTigecycline
PfizerTigecycline
PfizerStudy Evaluating the Etiology of Intra-Abdominal Infections

Clinical Trials (7)

Total enrollment: 2,342 patients across 7 trials

NCT01721408PfizerTigecycline

A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

Start: Nov 2012Est. completion: Oct 2015470 patients
Phase 4Completed
NCT00488761PfizerTigecycline

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI

Start: Jul 2006Est. completion: Aug 200750 patients
Phase 4Completed
NCT00081575PfizerTigecycline

Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

Start: Jan 2004Est. completion: Mar 2005434 patients
Phase 3Completed
NCT00079989PfizerTigecycline

Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms

Start: Dec 2003Est. completion: Nov 2005115 patients
Phase 3Completed
NCT00079885PfizerTigecycline

Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia

Start: Nov 2003Est. completion: Jul 2005430 patients
Phase 3Completed
NCT00228410PfizerTigecycline

Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections

Start: Nov 2002Est. completion: Dec 2003503 patients
Phase 3Completed
NCT00244088PfizerStudy Evaluating the Etiology of Intra-Abdominal Infections

Study Evaluating the Etiology of Intra-Abdominal Infections

Start: Apr 2004Est. completion: Dec 2004340 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.